All In Biotech

Drug Trial Radar · NCT03630952

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)

Last checked: Nov 20, 2026Latest source record: Jun 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 1,157 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,157

Actual

Start

Dec 21, 2018

Primary completion

Sep 10, 2020

Study completion May 19, 2021

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • 0.5 mg Conbercept Intravitreal InjectionBiological

    Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

  • 1.0 mg Conbercept Intravitreal InjectionBiological

    Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

  • 2.0 mg Aflibercept Intravitreal InjectionBiological

    Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eyeTime frame: Baseline to Week 36

Locations

154 sites in 12 countries. Site status is shown where the registry gives one.

  • Kanghong Investigative Site

    Phoenix, Arizona

  • Kanghong Investigative Site

    Phoenix, Arizona

  • Kanghong Investigative Site

    Springdale, Arkansas

  • Kanghong Investigative Site

    Arcadia, California

  • Kanghong Investigative Site

    Arcadia, California

  • Kanghong Investigative Site

    Bakersfield, California

  • Kanghong Investigative Site

    Encino, California

  • Kanghong Investigative Site

    Glendale, California

  • Kanghong Investigative Site

    Glendora, California

  • Kanghong Investigative Site

    Huntington Beach, California

  • Kanghong Investigative Site

    Pasadena, California

  • Kanghong Investigative Site

    Poway, California

  • Kanghong Investigative Site

    Redlands, California

  • Kanghong Investigative Site

    Redlands, California

  • Kanghong Investigative Site

    Riverside, California

  • Kanghong Investigative Site

    San Francisco, California

  • Kanghong Investigative Site

    Santa Barbara, California

  • Kanghong Investigative Site

    Colorado Springs, Colorado

  • Kanghong Investigative Site

    Waterford, Connecticut

  • Kanghong Investigative Site

    Boynton Beach, Florida

  • Kanghong Investigative Site

    Bradenton, Florida

  • Kanghong Investigative Site

    Miami, Florida

  • Kanghong Investigative Site

    Miami, Florida

  • Kanghong Investigative Site

    Stuart, Florida

  • Kanghong Investigative Site

    Winter Haven, Florida

  • Kanghong Investigative Site

    Atlanta, Georgia

  • Kanghong Investigative Site

    Augusta, Georgia

  • Kanghong Investigative Site

    Marietta, Georgia

  • Kanghong Investigative Site

    Elmhurst, Illinois

  • Kanghong Investigative Site

    Indianapolis, Indiana

  • Kanghong Investigative Site

    New Albany, Indiana

  • Kanghong Investigative Site

    Leawood, Kansas

  • Kanghong Investigative Site

    Springfield, Massachusetts

  • Kanghong Investigative Site

    Grand Rapids, Michigan

  • Kanghong Investigative Site

    Traverse City, Michigan

  • Kanghong Investigative Site

    St Louis, Missouri

  • Kanghong Investigative Site

    Reno, Nevada

  • Kanghong Investigative Site

    Northfield, New Jersey

  • Kanghong Investigative Site

    Teaneck, New Jersey

  • Kanghong Investigative Site

    Albuquerque, New Mexico

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.